Home > Newsletters > FDAnews Drug Daily Bulletin > Gilead’s PAH Candidate Scrapped After Missing Primary Endpoint in Study
FDAnews Drug Daily Bulletin
Aug. 24, 2012 | Vol. 9 No. 167
Gilead’s PAH Candidate Scrapped After Missing Primary Endpoint in Study
Gilead Sciences’ pulmonary arterial hypertension (PAH) drug cicletanine did not meet its primary endpoint in a Phase II trial, leading Gilead to terminate the study and drop plans to further develop the drug for PAH. Cicletanine, an oral, once-daily drug approved in some EU countries to treat hypertension, was not significantly better than placebo for helping patients with PAH walk farther in a six-minute walking test at 12 weeks.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.